Literature DB >> 30935235

Chromium exposure disrupts chromatin architecture upsetting the mechanisms that regulate transcription.

Hesbon A Zablon1, Andrew VonHandorf1, Alvaro Puga1.   

Abstract

IMPACT STATEMENT: This mini-review highlights current evidence on the mechanisms through which hexavalent chromium (Cr(VI)) disrupts transcriptional regulation, an emerging area of interest and one of the central processes by which chromium induces carcinogenesis. Several studies have shown that Cr(VI) causes widespread DNA damage and disrupts epigenetic signatures, suggesting that chromatin may be a direct Cr(VI) target. The findings discussed here suggest that Cr(VI) disrupts transcriptional regulation by causing genomic architecture changes.

Entities:  

Keywords:  Epigenetics; chromatin; genotoxicity; mechanisms; toxicology; transcription

Mesh:

Substances:

Year:  2019        PMID: 30935235      PMCID: PMC6567585          DOI: 10.1177/1535370219839953

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  53 in total

1.  Differential effects of arsenic(III) and chromium(VI) on nuclear transcription factor binding.

Authors:  R C Kaltreider; C A Pesce; M A Ihnat; J P Lariviere; J W Hamilton
Journal:  Mol Carcinog       Date:  1999-07       Impact factor: 4.784

2.  Mechanisms of chromium-induced suppression of RNA synthesis in cellular and cell-free systems: relationship to RNA polymerase arrest.

Authors:  Jian Xu; Francis C R Manning; Travis J O'Brien; Susan Ceryak; Steven R Patierno
Journal:  Mol Cell Biochem       Date:  2004-01       Impact factor: 3.396

3.  Chromium(VI) inhibits the transcriptional activity of nuclear factor-kappaB by decreasing the interaction of p65 with cAMP-responsive element-binding protein-binding protein.

Authors:  J A Shumilla; R J Broderick; Y Wang; A Barchowsky
Journal:  J Biol Chem       Date:  1999-12-17       Impact factor: 5.157

4.  Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer.

Authors:  Mario F Fraga; Esteban Ballestar; Ana Villar-Garea; Manuel Boix-Chornet; Jesus Espada; Gunnar Schotta; Tiziana Bonaldi; Claire Haydon; Santiago Ropero; Kevin Petrie; N Gopalakrishna Iyer; Alberto Pérez-Rosado; Enrique Calvo; Juan A Lopez; Amparo Cano; Maria J Calasanz; Dolors Colomer; Miguel Angel Piris; Natalie Ahn; Axel Imhof; Carlos Caldas; Thomas Jenuwein; Manel Esteller
Journal:  Nat Genet       Date:  2005-03-13       Impact factor: 38.330

5.  Resistance to apoptosis, increased growth potential, and altered gene expression in cells that survived genotoxic hexavalent chromium [Cr(VI)] exposure.

Authors:  Daryl E Pritchard; Susan Ceryak; Keri E Ramsey; Travis J O'Brien; Linan Ha; Jamie L Fornsaglio; Dietrich A Stephan; Steven R Patierno
Journal:  Mol Cell Biochem       Date:  2005-11       Impact factor: 3.396

6.  Activation of JNK, p38 and ERK mitogen-activated protein kinases by chromium(VI) is mediated through oxidative stress but does not affect cytotoxicity.

Authors:  S M Chuang; G Y Liou; J L Yang
Journal:  Carcinogenesis       Date:  2000-08       Impact factor: 4.944

7.  Gene expression profile in response to chromium-induced cell stress in A549 cells.

Authors:  J Ye; X Shi
Journal:  Mol Cell Biochem       Date:  2001-06       Impact factor: 3.396

8.  Chromium(VI) down-regulates heavy metal-induced metallothionein gene transcription by modifying transactivation potential of the key transcription factor, metal-responsive transcription factor 1.

Authors:  Sarmila Majumder; Kalpana Ghoshal; Dennis Summers; Shoumei Bai; Jharna Datta; Samson T Jacob
Journal:  J Biol Chem       Date:  2003-04-25       Impact factor: 5.157

9.  Epigenetic and gene expression changes related to transgenerational carcinogenesis.

Authors:  Robert Y-S Cheng; Tyler Hockman; Erik Crawford; Lucy M Anderson; Yih-Horng Shiao
Journal:  Mol Carcinog       Date:  2004-05       Impact factor: 4.784

10.  Selective activation of Src family kinases and JNK by low levels of chromium(VI).

Authors:  Kimberley A O'Hara; Linda R Klei; Aaron Barchowsky
Journal:  Toxicol Appl Pharmacol       Date:  2003-08-01       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.